Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: PF-02545920; Drug: placebo; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01103726

A8241013

Details and patient eligibility

About

We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.

Enrollment: 34 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy right-handed male and female subjects between the ages of 18 and 55 years, inclusive
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
• An informed consent document signed and dated by the subject
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion criteria

• Women of reproductive potential
• History of agranulocytosis or movement disorder
• Positron Emission Tomography (PET) or Magnetic Resonance Imaging (MRI) contraindications

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

34 participants in 2 patient groups

Stage 1

Experimental group

Treatment:

Drug: PF-02545920

Drug: placebo

Drug: PF-02545920

Drug: PF-02545920

Stage 2

Experimental group

Treatment:

Drug: PF-02545920

Drug: Placebo

Drug: PF-02545920

Drug: PF-02545920